

See discussions, stats, and author profiles for this publication at: <https://www.researchgate.net/publication/380267014>


HIV and Hemophilia: Addressing Stigma and Discrimination

Article · May 2024


CITATIONS
0

READS
26

2 authors:



Emmanuel Ifeanyi Obeagu
Kampala International University (KIU)
1,630 PUBLICATIONS 21,998 CITATIONS
[SEE PROFILE](#)



Sharon Seni Itoe Ngomo
University of Buea
4 PUBLICATIONS 4 CITATIONS
[SEE PROFILE](#)

HIV and Hemophilia: Addressing Stigma and Discrimination

*Emmanuel Ifeanyi Obeagu¹ and Sharon Seni Itoe Ngomo²

¹Department of Medical Laboratory Science, Kampala International University, Uganda

²Department of Microbiology and Parasitology, University of Buea, Buea, Cameroon

*Corresponding authour: Emmanuel Ifeanyi Obeagu, [Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161](#)

Abstract

Hemophilia and HIV, two chronic conditions with unique challenges, intersect in individuals who are doubly burdened by both their genetic predisposition to bleeding disorders and the acquired immunodeficiency virus. Beyond the physiological complexities of managing these conditions, individuals with hemophilia and HIV often face stigma and discrimination, exacerbating their already challenging circumstances. Misinformation, fear, and lack of awareness about these conditions perpetuate stereotypes and misconceptions, leading to social exclusion and discrimination. Historical experiences, such as the tainted blood scandal and the early stigma associated with HIV/AIDS, continue to shape perceptions and attitudes towards affected individuals, underscoring the enduring impact of past events on present-day stigma and discrimination. Addressing stigma and discrimination requires multifaceted strategies that encompass individual, community, and systemic levels of intervention. Education and awareness-raising initiatives play a crucial role in dispelling myths and misinformation about hemophilia and HIV, promoting empathy, and fostering supportive environments. Moreover, psychosocial support services, advocacy efforts, and policy interventions are essential for addressing structural barriers, challenging discriminatory practices, and promoting social inclusion and equity for individuals living with hemophilia and HIV.

Keywords: *HIV, hemophilia, stigma, discrimination, healthcare, psychosocial, advocacy, policy*

Introduction

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

Hemophilia, a hereditary bleeding disorder characterized by deficiencies in clotting factors, and HIV, a viral infection that compromises the immune system, represent two distinct yet intersecting challenges in the realm of healthcare. Historically, individuals affected by hemophilia have faced significant health concerns related to uncontrolled bleeding, joint damage, and impaired quality of life. With the emergence of HIV/AIDS in the early 1980s, the landscape of hemophilia care was forever altered as contaminated blood products became a major route of HIV transmission among individuals with hemophilia. Consequently, many individuals within the hemophilia community found themselves battling two formidable adversaries simultaneously: the inherent challenges of hemophilia and the life-threatening implications of HIV infection. Despite significant advancements in treatment and care for both hemophilia and HIV, individuals living with both conditions continue to face profound physical, emotional, and social burdens. The convergence of hemophilia and HIV presents a unique set of challenges that extend beyond the physiological aspects of managing these conditions. Stigma and discrimination, rooted in fear, ignorance, and prejudice, compound the already complex experiences of individuals living with hemophilia and HIV, exacerbating social isolation, undermining healthcare access, and perpetuating disparities in care.¹⁻²⁰

Stigma, characterized by negative attitudes, beliefs, and stereotypes, leads to the marginalization and social exclusion of affected individuals, contributing to their experiences of discrimination and social injustice. These challenges are further compounded by intersecting forms of stigma, including homophobia, racism, and poverty, which exacerbate the experiences of marginalization and discrimination faced by already vulnerable populations within the hemophilia and HIV communities. Moreover, the historical context surrounding hemophilia and HIV/AIDS has profoundly influenced perceptions, attitudes, and responses to these conditions, shaping societal narratives and contributing to the perpetuation of stigma and discrimination. The tainted blood scandal, in which thousands of individuals with hemophilia were infected with HIV through contaminated blood products, resulted in widespread fear, panic, and stigmatization of affected individuals. Similarly, the early years of the HIV/AIDS epidemic were characterized by misinformation, fear-mongering, and discrimination, further fueling the stigmatization of individuals living with HIV/AIDS and their communities.²¹⁻⁴⁰

Stigma and Discrimination

Stigma and discrimination against individuals living with hemophilia and HIV are multifaceted phenomena deeply rooted in societal attitudes, beliefs, and perceptions about these conditions. Stigma refers to the negative attitudes, stereotypes, and prejudices directed towards individuals or groups based on certain characteristics or attributes, while discrimination involves the differential treatment or exclusion of individuals as a result of stigma. In the context of hemophilia and HIV, stigma often arises from fear, misinformation, and misconceptions about these conditions, leading to social exclusion, marginalization, and discrimination. One of the primary drivers of stigma surrounding hemophilia and HIV is the fear of contagion and transmission. Misconceptions about the routes of transmission for both conditions, including beliefs that hemophilia is contagious or that HIV can be easily transmitted through casual contact, contribute to the stigmatization of affected individuals. These misconceptions fuel fear, anxiety, and avoidance behaviors, leading to

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

social distancing, isolation, and discrimination against individuals living with hemophilia and HIV. Moreover, the historical association of hemophilia with contaminated blood products and the early stigma surrounding HIV/AIDS have further contributed to the perpetuation of stigma and discrimination against affected individuals.⁴¹⁻⁶⁰

The intersectionality of stigma experienced by individuals with hemophilia and HIV is compounded by intersecting forms of discrimination based on factors such as race, sexual orientation, and socioeconomic status. Marginalized populations within the hemophilia and HIV communities, including people of color, LGBTQ+ individuals, and those living in poverty, face heightened levels of stigma and discrimination due to intersecting forms of oppression and discrimination. Discriminatory practices, such as denial of healthcare services, employment discrimination, and social ostracism, further exacerbate the challenges faced by already vulnerable populations, perpetuating health inequities and disparities in care. Addressing stigma and discrimination requires multifaceted strategies that encompass individual, community, and systemic levels of intervention. Education and awareness-raising initiatives play a crucial role in dispelling myths and misconceptions about hemophilia and HIV, promoting empathy, and fostering supportive environments. Moreover, advocacy efforts aimed at challenging discriminatory policies and practices, promoting inclusive healthcare services, and amplifying the voices of affected individuals are essential for driving systemic change and fostering social justice. By addressing stigma and discrimination head-on, we can create more inclusive and supportive environments that empower individuals living with hemophilia and HIV to live fulfilling lives free from discrimination.⁶¹⁻⁸⁰

Factors Contributing to Stigma and Discrimination

Stigma and discrimination against individuals living with hemophilia and HIV are influenced by a myriad of complex factors rooted in societal attitudes, historical contexts, and individual perceptions. Understanding these contributing factors is essential for developing targeted interventions to address stigma and discrimination and promote greater social inclusion and equity for affected individuals. One of the primary factors contributing to stigma and discrimination surrounding hemophilia and HIV is the presence of misinformation, myths, and misconceptions about these conditions within society. Lack of accurate knowledge about the causes, modes of transmission, and treatment options for hemophilia and HIV leads to fear, uncertainty, and prejudice towards affected individuals. Misinformation may perpetuate stereotypes and misconceptions, such as the belief that hemophilia is a result of promiscuity or that HIV can be transmitted through casual contact, further fueling stigmatization and discrimination. Historical experiences and societal narratives also play a significant role in shaping perceptions and attitudes towards individuals living with hemophilia and HIV. The tainted blood scandal, in which thousands of individuals with hemophilia were infected with HIV through contaminated blood products, resulted in widespread fear, panic, and stigmatization of affected individuals. Similarly, the early years of the HIV/AIDS epidemic were marked by misinformation, fear-mongering, and discrimination, leading to social ostracism and marginalization of individuals living with

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

HIV/AIDS. These historical events continue to influence societal attitudes and responses to hemophilia and HIV, contributing to the perpetuation of stigma and discrimination.⁸¹⁻¹⁰⁰

Furthermore, intersecting forms of stigma, such as homophobia, racism, and poverty, compound the experiences of stigma and discrimination faced by marginalized populations within the hemophilia and HIV communities. LGBTQ+ individuals, people of color, and those living in poverty may face additional layers of discrimination and social exclusion due to intersecting forms of oppression and marginalization. Discriminatory practices, such as denial of healthcare services, employment discrimination, and social ostracism, further exacerbate the challenges faced by already vulnerable populations, perpetuating health inequities and disparities in care. Addressing stigma and discrimination requires comprehensive strategies that encompass education, awareness-raising, advocacy, and policy interventions aimed at challenging discriminatory attitudes and promoting greater social inclusion and equity. By addressing the underlying factors contributing to stigma and discrimination, we can create more supportive and inclusive environments that empower individuals living with hemophilia and HIV to live fulfilling lives free from discrimination.¹⁰¹⁻¹¹⁰

Impacts of Stigma and Discrimination

Stigma and discrimination against individuals living with hemophilia and HIV have far-reaching consequences that extend beyond the individual level, impacting their physical health, emotional well-being, and social integration. These impacts are profound and multifaceted, affecting various aspects of individuals' lives and perpetuating health disparities and social inequities. At the individual level, stigma and discrimination can have detrimental effects on the physical health of individuals living with hemophilia and HIV. Fear of disclosure and discrimination may deter individuals from seeking healthcare services, adhering to treatment regimens, or disclosing their status to healthcare providers. This can lead to delays in diagnosis and treatment, exacerbation of health conditions, and poor treatment outcomes. Moreover, internalized stigma and shame may contribute to increased stress, anxiety, and depression, further compromising individuals' overall well-being and quality of life. In addition to their impact on physical health, stigma and discrimination also affect individuals' emotional well-being and mental health. Living with the constant fear of rejection, judgment, and social ostracism can take a toll on individuals' self-esteem, self-worth, and sense of belonging. Internalized stigma may lead to feelings of shame, guilt, and self-blame, contributing to psychological distress and mental health issues such as depression, anxiety, and social withdrawal. Moreover, experiences of discrimination in various settings, including healthcare, education, and employment, can lead to feelings of anger, frustration, and hopelessness, further exacerbating individuals' emotional distress and undermining their overall quality of life.¹¹¹⁻¹³⁰

Furthermore, stigma and discrimination perpetuate social inequities and disparities in access to healthcare, social support, and opportunities for individuals living with hemophilia and HIV. Discriminatory practices, such as denial of healthcare services, employment discrimination, and social exclusion, limit individuals' access to essential resources and support networks, exacerbating existing vulnerabilities and marginalization. Moreover, intersecting forms of stigma,

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

such as racism, homophobia, and poverty, compound the experiences of discrimination faced by marginalized populations within the hemophilia and HIV communities, further perpetuating health inequities and disparities in care. Addressing the impacts of stigma and discrimination requires multifaceted strategies that encompass individual, community, and systemic levels of intervention. By raising awareness, challenging stereotypes, and promoting empathy, we can create more supportive and inclusive environments that empower individuals living with hemophilia and HIV to seek care, access support services, and live fulfilling lives free from discrimination. Moreover, advocacy efforts aimed at challenging discriminatory policies and practices, promoting social inclusion, and amplifying the voices of affected individuals are essential for driving systemic change and fostering social justice in healthcare and beyond.¹³¹⁻¹³⁵

Strategies for Addressing Stigma and Discrimination

Addressing stigma and discrimination against individuals living with hemophilia and HIV requires multifaceted approaches that encompass education, advocacy, policy change, and community engagement. By addressing the underlying factors contributing to stigma and discrimination and promoting greater awareness, understanding, and acceptance, we can create more inclusive and supportive environments that empower affected individuals and promote social justice. Education and Awareness-Raising Initiatives: Education plays a crucial role in dispelling myths, misconceptions, and stereotypes about hemophilia and HIV, promoting accurate knowledge and understanding among the general public. Educational campaigns, workshops, and outreach programs can help raise awareness about the causes, modes of transmission, and treatment options for hemophilia and HIV, fostering empathy, compassion, and support for affected individuals. Moreover, incorporating education about stigma and discrimination into school curricula and healthcare training programs can help equip future generations with the knowledge and skills to challenge prejudice and promote inclusivity.¹³⁶⁻¹⁴⁰

Promotion of Positive Messaging and Representation: Positive messaging and representation of individuals living with hemophilia and HIV can help counteract negative stereotypes and promote empathy and understanding. Media campaigns, storytelling initiatives, and advocacy efforts that highlight the resilience, strength, and diversity of affected individuals can challenge stigma and discrimination, promote social inclusion, and foster greater acceptance and support within society. Moreover, fostering positive role models and leadership opportunities for individuals living with hemophilia and HIV can empower them to advocate for their rights, challenge stigma, and inspire others within their communities. Community-Based Support and Peer Networks: Peer support networks and community-based organizations offer invaluable opportunities for individuals living with hemophilia and HIV to connect with others, share experiences, and access information, resources, and support in a safe and supportive environment. Peer support programs, support groups, and online forums provide opportunities for individuals to receive emotional support, practical guidance, and encouragement from peers who understand their experiences firsthand. Moreover, community-based organizations play a vital role in advocating for the rights and needs of affected individuals, promoting social inclusion, and driving systemic change. Advocacy for Policy Change and Structural Reform: Advocacy efforts aimed at challenging discriminatory policies and practices, promoting inclusive healthcare services, and amplifying the voices of

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. Elite Journal of Public Health, 2024; 2 (5): 1-20

affected individuals are essential for driving systemic change and fostering social justice. Advocacy organizations, civil society groups, and grassroots movements play a pivotal role in advocating for policy change, legislative reform, and the implementation of anti-discrimination measures at local, national, and international levels. Moreover, engaging policymakers, healthcare providers, and other stakeholders in dialogue and collaboration can help build alliances, mobilize resources, and foster collective action to address stigma and discrimination effectively.¹⁴¹⁻¹⁵⁰

Integrating Psychosocial Support into Care

Recognizing the profound impact of stigma and discrimination on the well-being of individuals living with hemophilia and HIV, it is imperative to prioritize the integration of psychosocial support into their care. Psychosocial support services encompass a range of interventions aimed at addressing the emotional, social, and practical needs of affected individuals and promoting their overall well-being. By providing holistic support that addresses the psychological, social, and emotional aspects of living with chronic illness, psychosocial support can enhance coping skills, improve resilience, and foster a sense of empowerment among individuals living with hemophilia and HIV. One essential component of psychosocial support is counseling and therapy, which provides individuals with a safe and confidential space to explore their feelings, concerns, and coping strategies in relation to their hemophilia and HIV diagnosis. Counseling can help individuals process their emotions, develop coping skills, and navigate the challenges of living with chronic illness, empowering them to better manage stress, anxiety, and depression. Moreover, therapy can address issues related to stigma, discrimination, and identity, helping individuals develop strategies for coping with societal attitudes and building resilience in the face of adversity.¹⁵¹⁻¹⁵⁵

Peer support programs offer another valuable avenue for psychosocial support, connecting individuals living with hemophilia and HIV with others who share similar experiences and challenges. Peer support networks provide opportunities for individuals to share their stories, exchange advice and practical tips, and receive emotional support and validation from others who understand their journey firsthand. By fostering a sense of belonging, empathy, and solidarity, peer support programs can reduce feelings of isolation, enhance social connectedness, and promote resilience among affected individuals. In addition to individual counseling and peer support, group-based interventions, such as support groups and psychoeducational workshops, can provide valuable opportunities for individuals to learn from one another, share experiences, and build coping skills in a supportive group setting. These interventions may cover a range of topics, including stress management, communication skills, self-care strategies, and advocacy skills, empowering individuals to take an active role in managing their health and well-being. Moreover, group-based interventions can foster a sense of community, camaraderie, and mutual support among participants, reinforcing positive coping strategies and promoting resilience in the face of adversity. Furthermore, psychosocial support should be integrated into routine healthcare services for individuals living with hemophilia and HIV, ensuring that psychosocial needs are addressed alongside medical treatment and management. Healthcare providers play a crucial role in assessing psychosocial needs, providing emotional support, and connecting individuals with appropriate resources and services. By adopting a holistic approach to care that addresses the physical,

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. Elite Journal of Public Health, 2024; 2 (5): 1-20

emotional, and social aspects of living with chronic illness, healthcare providers can optimize treatment outcomes, improve quality of life, and promote resilience among individuals living with hemophilia and HIV.¹⁵⁶⁻¹⁶⁰

Policy Implications and Future Directions

Addressing stigma and discrimination against individuals living with hemophilia and HIV requires coordinated efforts across multiple sectors, including healthcare, education, employment, and social services. Policy interventions aimed at protecting the rights of affected individuals, promoting social inclusion, and challenging discriminatory practices are essential for creating supportive environments and fostering social change. Moreover, continued research, advocacy, and collaboration are necessary to advance our understanding of stigma and discrimination and identify effective strategies for addressing these issues in the future. One key policy implication is the need for legislative reform to protect the rights and promote the well-being of individuals living with hemophilia and HIV. Anti-discrimination laws and policies can help ensure equal access to healthcare, employment, education, and other essential services for affected individuals, regardless of their health status. Moreover, policies that promote inclusive practices, such as workplace accommodations and accessible healthcare services, can help create environments that support the needs of individuals living with hemophilia and HIV and foster greater social inclusion.¹⁶¹⁻¹⁶⁷

Furthermore, investments in education and awareness-raising initiatives are essential for challenging stigma and discrimination and promoting greater understanding and acceptance of hemophilia and HIV within society. Educational campaigns, school curricula, and training programs for healthcare providers can help dispel myths and misconceptions, foster empathy, and promote positive attitudes towards affected individuals. Moreover, media campaigns, storytelling initiatives, and community engagement efforts can raise awareness about the experiences and challenges faced by individuals living with hemophilia and HIV, promoting greater empathy and support within society. In addition to legislative reform and education, efforts to promote social inclusion and support the needs of affected individuals require collaboration and partnership across sectors. Healthcare providers, policymakers, advocacy organizations, community leaders, and affected individuals themselves must work together to develop and implement comprehensive strategies for addressing stigma and discrimination. By fostering collaboration and partnership, we can leverage collective expertise, resources, and networks to drive systemic change and create more inclusive and supportive environments for individuals living with hemophilia and HIV. Looking towards the future, it is essential to continue research initiatives aimed at understanding the drivers and impacts of stigma and discrimination and identifying effective interventions for addressing these issues. Longitudinal studies, qualitative research, and community-based participatory research can provide valuable insights into the experiences, needs, and preferences of affected individuals and inform evidence-based approaches for addressing stigma and discrimination in clinical, social, and policy contexts. Moreover, investments in innovative interventions, such as digital health tools, peer support networks, and community-based programs, can help expand access to psychosocial support services and promote resilience among individuals living with hemophilia and HIV.¹⁵⁰⁻¹⁵⁶

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

Conclusion

Stigma and discrimination against individuals living with hemophilia and HIV pose significant challenges that undermine their health, well-being, and social integration. Despite advancements in medical treatment and care, the pervasive influence of stigma and discrimination continues to impact affected individuals, perpetuating social inequities and hindering efforts to promote their rights and dignity. Addressing stigma and discrimination requires comprehensive and coordinated approaches that encompass education, advocacy, policy reform, and community engagement. By raising awareness, challenging stereotypes, and promoting empathy, we can create more supportive and inclusive environments that empower affected individuals and foster greater social acceptance and understanding. Moreover, policy interventions aimed at protecting the rights of affected individuals, promoting social inclusion, and challenging discriminatory practices are essential for driving systemic change and fostering social justice. Legislative reform, education initiatives, and collaborative partnerships across sectors are necessary to create environments that support the needs of individuals living with hemophilia and HIV and promote their full participation in society.

References

1. Menegatti M, Peyvandi F. Treatment of rare factor deficiencies other than hemophilia. *Blood*, The Journal of the American Society of Hematology. 2019;133(5):415-524.
2. Patton LL. Bleeding and clotting disorders. *Burket's oral medicine: diagnosis and treatment*. 10th ed. Hamilton (ON): BC Decker. 2003:454-477.
3. Livanou ME, Matsas A, Valsami S, Papadimitriou DT, Kontogiannis A, Christopoulos P. Clotting Factor Deficiencies as an Underlying Cause of Abnormal Uterine Bleeding in Women of Reproductive Age: A Literature Review. *Life*. 2023;13(6):1321.
4. Bauer KA. Current challenges in the management of hemophilia. *Am J Manag Care*. 2015;21(6 Suppl):S112-22.
5. Berntorp E, Fischer K, Hart DP, Mancuso ME, Stephensen D, Shapiro AD, Blanchette V. Haemophilia. *Nature reviews Disease primers*. 2021 Jun 24;7(1):45.
6. Karim MA, Jamal CY. A review on hemophilia in children. *Bangladesh J Child Health*. 2013;37(1):27-40.
7. Obeagu EI. Haemophilia B: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2022;9(1):14-20.
8. Okoroiwu IL, Obeagu EI, Egbuobi LN, Ibekwe AM, Vincent CC, Unaeze BC, Adike CN, Chijioke UO, Okafor CJ, Soremi AO, Chukwurah EF. Evaluation of Factor VIII and Factor IX Activity among Primary School Children in Owerri, Imo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021 Jul 3;33(34B):235-41.
9. Obeagu EI, Obeagu GU, Musiimenta E. Post partum haemorrhage among pregnant women: Update on risks factors. *Int. J. Curr. Res. Med. Sci*. 2023;9(2):14-7.
10. Obeagu EI, Eze RI, Nwakulite A, Obeagu GU, Babar Q. AN UPDATE ON HAEMOPHILIA A. A. *Journal of Medicine and Health Sciences*. 2021;1(1):7-18.

11. Obeagu EI, Obeagu GU. Postpartum haemorrhage among women delivering through spontaneous vaginal delivery: Prevalence and risk factors. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(8):22-6.
12. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-6.
13. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015;3:139-44.
14. Obeagu EI, Obeagu GU, Kama SC. Fibrin degradation product and Haemorrhage. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2022;9(1):21-7.
15. Obeagu E, Nwosu D, Obeagu III G. Antithrombin III: A Review. *Int. J. Curr. Res. Biol. Med.* 2022;7(2):20-7.
16. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):120-127.
17. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023 ;3(1):7-12.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
18. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri.* 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
19. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-19.
20. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci.* 2017;3(1): 21-38.DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
21. McCann SR. *A History of haematology: from Herodotus to HIV.* Oxford University Press; 2016.
22. McCann SR. *A History of haematology: from Herodotus to HIV.* Oxford University Press; 2016.
23. Provan D. *Oxford handbook of clinical haematology.* Oxford University Press, USA; 2009.
24. Doering CB, Archer D, Spencer HT. Delivery of nucleic acid therapeutics by genetically engineered hematopoietic stem cells. *Advanced drug delivery reviews.* 2010;62(12):1204-1212.
25. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
26. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community

- Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
27. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
28. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
29. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
30. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916.
[https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
31. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
32. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
[links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf)
33. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
34. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov*. 2016;5(1):24-30.
[links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
35. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015; 3:139-144.
[https://www.academia.edu/download/38320159/Obeagu Emmanuel Ifeanyi3 et al.IJC RAR.pdf](https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al.IJC_RAR.pdf).

36. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4.
[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://epjournals.com/journals/EJPH/links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf)
37. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
38. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
39. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139.
[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://epjournals.com/journals/EJPH/links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf).
40. Adeyemo TA, Adeyemo WL, Adediran A, Abd Jaleel AA, Akanmu AS. Orofacial manifestations of hematological disorders: Anemia and hemostatic disorders. Indian Journal of Dental Research. 2011;22(3):454-461.
41. Jayandharan GR, Srivastava A. The phenotypic heterogeneity of severe hemophilia. In Seminars in thrombosis and hemostasis 2008; 01: 128-141.
42. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clinical chemistry. 2003;49(10):1573-1578.
43. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134.
<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
44. Walter O, Anaebio QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022;29-34.
45. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Bassey JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
46. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137.
[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://epjournals.com/journals/EJPH/links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf).
47. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI:

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. Elite Journal of Public Health, 2024; 2 (5): 1-20

- 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://epjournals.com/journals/EJPH/links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf)
48. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci.* 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://epjournals.com/journals/EJPH/links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf).
49. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 [https://www.academia.edu/download/54317126/Haematological indices of malaria patients coinfectd with HIV.pdf](https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfectd_with_HIV.pdf)
50. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology.* 2022;13(2):26-31.
51. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med.* 2020;2(3):180-183.DOI: DOI: 10.32474/JCCM.2020.02.000137 [links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://epjournals.com/journals/EJPH/links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-ELISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).
52. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International.* 2021;33(47A):78-84.
53. Emannuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth.* 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
54. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International.* 2021;33(57A):360-368.
55. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
56. Echendu GE, Vincent CC, Ibebuikwe J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A

- PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023; 10(8): 564-568
57. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160.
[links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.wjpr.in/index.php/wjpr/article/view/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf).
 58. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
 59. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8.DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004)
[links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf](https://www.ijcreps.com/index.php/ijcreps/article/view/links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf).
 60. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13.DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002) [links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/index.php/ijcrms/article/view/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
 61. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/index.php/ijcrms/article/view/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
 62. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910.
[https://www.academia.edu/download/38320134/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma.EMMA2.pdf](https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf).
 63. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
 64. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14.
<https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
 65. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
 66. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebio QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal

- Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-189.
67. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
68. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-11.
69. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanna CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
70. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-108.
71. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-66.
72. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
73. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75.
74. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
75. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
76. Anyiam AF, Arinze-Anyiam OC, Ironi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
77. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
78. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.

79. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR,
80. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.
81. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
82. Obeagu EI, Obeagu GU. Unmasking the Truth: Addressing Stigma in the Fight Against HIV. *Elite Journal of Public Health.* 2024;2(1):8-22.
83. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. *Elite Journal of Immunology.* 2024;2(1):14-33.
84. Obeagu EI, Obeagu GU. Utilization of immunological ratios in HIV: Implications for monitoring and therapeutic strategies. *Medicine.* 2024;103(9): e37354.
85. Obeagu EI, Obeagu GU. CD8 Dynamics in HIV Infection: A Synoptic Review. *Elite Journal of Immunology.* 2024;2(1):1-3.
86. Obeagu EI, Obeagu GU. Implications of B Lymphocyte Dysfunction in HIV/AIDS. *Elite Journal of Immunology.* 2024;2(1):34-46.
87. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine.* 2024;2(1):46-58.
88. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine.* 2024;2(1):35-46.
89. Obeagu EI, Obeagu GU. Platelet-Driven Modulation of HIV: Unraveling Interactions and Implications. *Journal home page: <http://www.journalijar.com>;*12(01).
90. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV.* 2024;2(1):65-78.
91. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijar.com>;*12(01).
92. Obeagu EI, Obeagu GU. Synergistic Effects of Blood Transfusion and HIV in Children Under 5 Years with Severe Malaria: A Review. *Elite Journal of HIV.* 2024;2(1):31-50.
93. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV.* 2024;2(1):1-5.
94. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci.* 2024;10(1):25-36.
95. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences.* 2024;4(1):32-7.
96. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences.* 2024;4(1):38-44.
97. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science.* 2024;2(1):33-42.

98. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
99. Gonzalez VD. Innate and adaptive cellular immunity in chronic HCV and HIV-1 infection. Karolinska Institutet (Sweden); 2009.
100. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-15.
101. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
102. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
103. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
104. Obeagu EI, Obeagu GU. Understanding Hematocrit Fluctuations in HIV-Malaria Coinfection for Improved Management. *Elite Journal of Public Health*. 2024;2(1):22-34.
105. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
106. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. *Journal home page*: [http://www.journalijiar.com](http://www.journalijiar.com;).;12(01).
107. Obeagu EI, Obeagu GU. Neonatal Outcomes in Children Born to Mothers with Severe Malaria, HIV, and Transfusion History: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):38-58.
108. Obeagu EI, Obeagu GU. Assessing Platelet Functionality in HIV Patients Receiving Antiretroviral Therapy: Implications for Risk Assessment. *Elite Journal of HIV*. 2024;2(3):14-26.
109. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. *Elite Journal of Public Health*. 2024;2(1):52-63.
110. Obeagu EI, Obeagu GU. Maternal Influence on Infant Immunological Responses to HIV: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):46-58.
111. Obeagu EI, Obeagu GU. Counting Cells, Shaping Fates: CD4/CD8 Ratios in HIV. *Elite Journal of Scientific Research and Review*. 2024;2(1):37-50.
112. Obeagu EI, Anyiam AF, Obeagu GU. Managing Hematological Complications in HIV: Erythropoietin Considerations. *Elite Journal of HIV*. 2024;2(1):65-78.
113. Obeagu EI, Obeagu GU. Immune Modulation in HIV-Positive Neonates: Insights and Implications for Clinical Management. *Elite Journal of Nursing and Health Science*. 2024;2(3):59-72.
114. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and Antiretroviral Therapy in HIV Management. *Elite Journal of Nursing and Health Science*. 2024;2(2):5-15.

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

115. Obeagu EI, Obeagu GU. Understanding B Lymphocyte Functions in HIV Infection: Implications for Immune Dysfunction and Therapeutic Strategies. *Elite Journal of Medicine*. 2024;2(1):35-46.
116. Obeagu EI, Anyanwu CN, Obeagu GU. Challenges and Considerations in Managing Blood Transfusion for Individuals with HIV. *Elite Journal of HIV*. 2024;2(2):1-7.
117. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. *Elite Journal of HIV*. 2024;2(2):60-73.
118. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*. 2024;2(1):10-22.
119. Obeagu EI, AmaezeAA O, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. *Elite Journal of Nursing and Health Science*. 2024;2(2):33-46.
120. Scott JA, Chew KW. Treatment optimization for HIV/HCV co-infected patients. *Therapeutic advances in infectious disease*. 2017;4(1):18-36.
121. Pooranangadevi N, Padmapriyadarsini C. Treatment of tuberculosis and the drug interactions associated with HIV-TB co-infection treatment. *Frontiers in Tropical Diseases*. 2022; 3:834013.
122. Obeagu EI, Obeagu GU. Eosinophil Dynamics in Pregnancy among Women Living with HIV: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):11-24.
123. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. *Int. J. Curr. Res. Med. Sci*. 2024;10(1):25-36.
124. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. *Elite Journal of Immunology*. 2024;2(3):33-44.
125. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. *Elite Journal of Immunology*. 2024;2(2):15-28.
126. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Neutrophil Dynamics: Unveiling Their Role in HIV Progression within Malaria Patients. *Journal home page: <http://www.journalijiar.com>;12(01)*.
127. Obeagu EI, Obeagu GU, Hauwa BA, Umar AI. Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review. *Journal home page: <http://www.journalijiar.com>;12(01)*.
128. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*. 2024;2(1):16-30.
129. Obeagu EI, Obeagu GU. Maternal Eosinophilic Responses in HIV-Positive Pregnant Women: Unraveling Immunological Dynamics for Improved Maternal-Fetal Health. *Elite Journal of Immunology*. 2024;2(1):47-64.
130. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. *Elite Journal of Haematology*, 2024; 2 (3):10-24.

131. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):33-45.
132. Obeagu EI, Anyiam AF, Obeagu GU. Erythropoietin Therapy in HIV-Infected Individuals: A Critical Review. *Elite Journal of HIV*. 2024;2(1):51-64.
133. Obeagu EI, Ubosi NI, Obeagu GU, Obeagu AA. Nutritional Strategies for Enhancing Immune Resilience in HIV: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):41-51.
134. Obeagu EI, Obeagu GU. The Crucial Role of Erythropoietin in Managing Anemia in HIV: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):24-36.
135. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV-Exposed Infants: A Review. *Elite Journal of Immunology*. 2024;2(3):1-8.
136. Obeagu EI, Anyiam AF, Obeagu GU. Unveiling B Cell Mediated Immunity in HIV Infection: Insights, Challenges, and Potential Therapeutic Avenues. *Elite Journal of HIV*. 2024;2(1):1-5.
137. Obeagu EI, Obeagu GU. Anemia and Erythropoietin: Key Players in HIV Disease Progression. *Elite Journal of Haematology*, 2024; 2 (3):42-57.
138. Obeagu EI, Obeagu GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. *Elite Journal of Scientific Research and Review*. 2024;2(1):1-6.
139. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. *Elite Journal of Public Health*. 2024;2(1):52-61.
140. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. *Sciences*. 2024;4(1):32-7.
141. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. *Elite Journal of Health Science*. 2024;2(2):16-29.
142. Obeagu EI, Obeagu GU. Mental Health and Psychosocial Effects of natural disaster on HIV Patients. *Sciences*. 2024;4(1):38-44.
143. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. *Elite Journal of Nursing and Health Science*. 2024;2(2):1-7.
144. Obeagu EI, Obeagu GU. Advances in Understanding the Impact of Blood Transfusion on Anemia Resolution in HIV-Positive Children with Severe Malaria: A Comprehensive Review. *Elite Journal of Haematology*. 2024;2(1):26-41.
145. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
146. Obeagu EI, Obeagu GU. Impact of Blood Transfusion on Viral Load Dynamics in HIV-Positive Neonates with Severe Malaria: A Review. *Elite Journal of Scientific Research and Review*. 2024;2(1):42-60.
147. Obeagu EI, Ayogu EE, Obeagu GU. Interactions between Blood Transfusion and Antiretroviral Medications: Implications for Patient Care. *Elite Journal of Medicine*. 2024;2(2):104-5.
148. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. *Elite Journal of Haematology*, 2024; 2 (3):25-41.

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

149. Obeagu EI, Obeagu GU. Eosinophil-Associated Changes in Neonatal Thymic T Regulatory Cell Populations in HIV-Infected Pregnancies. *Elite Journal of Health Science*. 2024;2(1):33-42.
150. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. *Elite Journal of HIV*. 2024;2(2):43-59.
151. Obeagu EI. Erythropoietin and the Immune System: Relevance in HIV Management. *Elite Journal of Health Science*. 2024;2(3):23-35.
152. Obeagu EI, Obeagu GU. The Impact of Erythropoietin on Preeclampsia in HIV-Positive Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(1):21-31.
153. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. *Elite Journal of Nursing and Health Science*. 2024;2(3):84-99.
154. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. *Elite Journal of Health Science*. 2024;2(2):20-35.
155. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies. *Elite Journal of Laboratory Medicine*. 2024;2(2):30-46.
156. Obeagu EI, Obeagu GU. The Intricate Relationship Between Erythropoietin and HIV-Induced Anemia: Unraveling Pathways for Therapeutic Insights. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):30-40.
157. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. *Elite Journal of Public Health*. 2024;2(1):35-51.
158. Kalu OA, Ukibe NR, Onyenekwe CC, Okoyeagu RC, Nnaemeka WS, Onyenekwe AJ, Ukibe EG, Ukibe BC, Ukibe VE, Obeagu EI. Assessment of Serum Cystatin C, Microalbumin Levels and Egfr in HIV Seropositive Individuals based on Age and Gender in NAUTH, Nnewi, Nigeria. *Elite Journal of Medicine*. 2024;2(3):48-59.
159. Obeagu EI, Obeagu GU. Understanding Immune Cell Trafficking in Tuberculosis-HIV Coinfection: The Role of L-selectin Pathways. *Elite Journal of Immunology*. 2024;2(2):43-59.
160. Obeagu EI, Obeagu GU. Eosinophilic Changes in Placental Tissues of HIV-Positive Pregnant Women: A Review. *Elite Journal of Laboratory Medicine*. 2024;2(1):14-32.
161. Obeagu EI, Obeagu GU. P-Selectin and Platelet Activation in HIV: Implications for Antiviral Therapy. *Elite Journal of Scientific Research and Review*. 2024;2(1):17-41.
162. Obeagu EI, Obeagu GU. Strength in Unity: Building Support Networks for HIV Patients in Uganda. *Elite Journal of Medicine*. 2024;2(1):1-6.
163. Obeagu EI, GU EE. Understanding the Intersection of Highly Active Antiretroviral Therapy and Platelets in HIV Patients: A Review. *Elite Journal of Haematology*, 2024; 2 (3):111-117.
164. Obeagu EI, Ngomo SSI. Erythrocyte Morphology in Hemophilia Patients Co-infected with HIV: A Review. *Elite Journal of Haematology*, 2024; 2(5): 72-89

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20

165. Obeagu EI. Reviewing Erythrocyte Morphology Changes in Hemophilia Patients with HIV: Current Insights. *Elite Journal of Haematology*, 2024; 2(5): 90-107
166. Obeagu EI, Ngomo SSI. Impact of HIV on Hemophilia Patients: A Review. *Elite Journal of HIV*, 2024; 2(5): 9-27
167. Obeagu EI, Ngomo SSI. HIV Co-infection in Hemophilia: Implications for Treatment. *Elite Journal of HIV*, 2024; 2(5): 28-46

Citation: Obeagu EI, Ngomo SSI. HIV and Hemophilia: Addressing Stigma and Discrimination. *Elite Journal of Public Health*, 2024; 2 (5): 1-20